CN112603982A - Composition for inhibiting prostatic hyperplasia - Google Patents

Composition for inhibiting prostatic hyperplasia Download PDF

Info

Publication number
CN112603982A
CN112603982A CN202011598714.9A CN202011598714A CN112603982A CN 112603982 A CN112603982 A CN 112603982A CN 202011598714 A CN202011598714 A CN 202011598714A CN 112603982 A CN112603982 A CN 112603982A
Authority
CN
China
Prior art keywords
prostatic hyperplasia
inhibiting
composition
parts
turmeric
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202011598714.9A
Other languages
Chinese (zh)
Inventor
杜玉兰
喻勤
严建刚
李晓敏
欧阳道福
余宗盛
魏毅凡
古润金
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Perfect China Co Ltd
Perfect Guangdong Commodity Co Ltd
Original Assignee
Perfect China Co Ltd
Perfect Guangdong Commodity Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Perfect China Co Ltd, Perfect Guangdong Commodity Co Ltd filed Critical Perfect China Co Ltd
Priority to CN202011598714.9A priority Critical patent/CN112603982A/en
Publication of CN112603982A publication Critical patent/CN112603982A/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
    • A23L2/385—Concentrates of non-alcoholic beverages
    • A23L2/39—Dry compositions
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A23L33/11—Plant sterols or derivatives thereof, e.g. phytosterols
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/906—Zingiberaceae (Ginger family)
    • A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Abstract

The invention discloses a composition for inhibiting prostatic hyperplasia, which belongs to the field of health food and comprises the following components: mixed tocopherols, lycopene and phytosterol esters, further comprising turmeric; the curcumin content in the turmeric is 40-60%. The turmeric, the lycopene, the mixed tocopherol and the phytosterol ester are compounded, and the synergistic interaction effect among the components can effectively inhibit the prostatic hyperplasia, and the effect is better than that of single use. In addition, the composition for inhibiting the prostatic hyperplasia has high safety and no toxic or side effect. The invention also provides a preparation method of the composition for inhibiting the prostatic hyperplasia, and the preparation method has simple preparation process and can be used for industrial mass production. The invention also provides application of the composition for inhibiting the prostatic hyperplasia in preparation of health food products for inhibiting the prostatic hyperplasia.

Description

Composition for inhibiting prostatic hyperplasia
Technical Field
The invention relates to the field of medical health-care food, in particular to a composition for inhibiting prostatic hyperplasia.
Background
Benign prostatic hyperplasia is a common middle-aged and old-aged male disease, is manifested by symptoms of frequent micturition, urgent micturition, unsmooth urination, increased nocturia, urinary retention and the like, may cause complications such as urinary tract infection, vesical calculus and the like, and even may cause renal function injury. The pathogenesis of prostatic hyperplasia is a very complex pathological process involving a plurality of factors, such as hormones, endocrine, growth factors, inflammatory factors, etc., and the pathogenesis of prostatic hyperplasia can be the result of the single dominant action of one of the factors or the combined action of the factors.
At present, the main methods for preventing and treating the prostatic hyperplasia diseases mainly carry out medicament treatment besides physical treatment and surgical treatment, and western medicaments such as antibiotics are mainly used for preventing and treating the prostatic hyperplasia diseases in the medicaments, so that the recurrence rate is high and certain side effects are caused.
It has been found that some plants contain active ingredients that have some effect on prostate disorders. Research on Chenzhi strong team of urology scientific research institute of the first subsidiary hospital of Guangxi medical university finds that curcumin has an induction effect on apoptosis of human prostatic hyperplasia interstitial cells, and the turmeric extract is proved to have a good effect of treating benign prostatic hyperplasia. The study of Leyi et al, a Jinling Hospital/general east war zone Hospital, affiliated to southern medical university, finds that lycopene has good curative effect on treating prostatic hyperplasia combined with lower urinary tract symptoms, and obviously improves the quality of life. In foreign countries, a randomized, double-blind, placebo-controlled clinical trial study designed by SCHWARZ et al indicates that supplementation with a certain amount of lycopene may achieve an anti-prostatic hyperplasia effect, and that lycopene may lower the PSA level in patients with benign prostatic hyperplasia, which may exert certain efficacy in preventing prostate cancer. In addition, the research of K.F. KLIPPEL et al at the university of Dreuston's science and technology shows that the beta-sitosterol (mainly from vegetable oil) also has the effect of improving the hyperplasia of prostate. However, there is no relevant literature or published technology to indicate that the effective components of the plants can be used together or can synergistically improve the problem of prostatic hyperplasia.
Disclosure of Invention
Based on the shortcomings of the prior art, the invention aims to provide a composition for inhibiting prostatic hyperplasia.
In order to achieve the purpose, the invention adopts the technical scheme that:
a composition for inhibiting prostatic hyperplasia comprises the following components: mixed tocopherols, lycopene and phytosterol esters, further comprising turmeric; the curcumin content in the turmeric is 40-60%.
The composition for inhibiting prostatic hyperplasia comprises dried rhizome extract of Curcuma rhizome (Curcuma longa L.) belonging to Curcuma of Zingiberaceae, and curcumin as main chemical component. The Curcuma rhizome has effects of resisting tumor, resisting oxidation, protecting liver, reducing blood sugar, resisting inflammation, resisting bacteria, and resisting virus; lycopene is one of carotenoid, and has effects in resisting oxidation, scavenging free radicals, protecting cardiovascular and cerebrovascular system, and enhancing immunity; the mixed tocopherol is natural vitamin E extracted from oil material, and has antioxidant, neuroprotective, antiinflammatory and cholesterol lowering effects; the phytosterol ester is mainly derived from vegetable oil such as soybean oil, rapeseed oil, corn oil, sunflower seed oil, tall oil and the like, is generally prepared by extracting phytosterol from the vegetable oil and performing esterification reaction on the phytosterol and fatty acid, the active ingredient of the phytosterol ester is the phytosterol, the main sterols comprise beta-sitosterol, stigmasterol, campesterol and the like, the phytosterol ester has the effects of reducing cholesterol, preventing cardiovascular diseases, resisting inflammation, resisting cancer and the like, and the contained sterols have similar structures with dihydrotestosterone and can compete with the dihydrotestosterone to inhibit the combination of the dihydrotestosterone and a receptor so as to improve the prostatic hyperplasia.
The composition for inhibiting the prostatic hyperplasia is prepared by matching the turmeric, the lycopene, the mixed tocopherol and the phytosterol ester, wherein the curcumin in the turmeric can inhibit inflammatory factors, can inhibit the proliferation of prostatic interstitial cells at the same time, induces the prostatic interstitial cells to undergo apoptosis, and can obviously reduce the wet weight of the prostate and reduce the prostate index; lycopene reduces DNA damage, improves oxidative stress defense; the mixed tocopherol can promote blood circulation and balance hormone level in vivo; the phytosterol ester has similar structure to dihydrotestosterone, and can compete with dihydrotestosterone to inhibit the binding of dihydrotestosterone to receptor, thereby improving prostatic hyperplasia. The four functional raw materials are compounded to realize the synergistic effect of multiple ways to improve the prostatic hyperplasia. In addition, the four components are common food raw materials or food additives, and the composition has high safety.
Preferably, the composition for inhibiting the prostatic hyperplasia comprises the following components in parts by weight: 12.5-50 parts of mixed tocopherol, 12.5-25 parts of lycopene, 12.5-25 parts of turmeric and 50-100 parts of phytosterol ester. Under the condition of the components in parts by weight, the inhibition efficiency of the collocation of the components on the prostatic hyperplasia is obviously improved. The composition prepared at this specific ratio has the highest efficiency of inhibiting prostatic hyperplasia.
The invention also aims to provide a preparation method of the composition for inhibiting the prostatic hyperplasia.
The preparation method of the composition for inhibiting the prostatic hyperplasia comprises the step of uniformly mixing the mixed tocopherol, the lycopene, the turmeric and the phytosterol ester to obtain the composition for inhibiting the prostatic hyperplasia.
The preparation method of the composition for inhibiting the prostatic hyperplasia, which is provided by the invention, has simple preparation process and can be industrially produced in a large scale.
Meanwhile, the four components in the composition can be prepared and extracted according to actual conditions, can be directly purchased from the market, and can be replaced by raw materials, semi-finished products or added finished products with the same components without influencing the efficacy of the prepared product: the Curcuma rhizome can be prepared from Curcuma rhizome; the mixed tocopherol can be replaced by one or a mixture of several tocopherols of different molecular formulas or compounds with similar structures; lycopene can be replaced by non-pure lycopene-rich substances extracted from plants, or by substances containing lycopene or structural analogs obtained by biological fermentation or chemical synthesis; the phytosterol ester can be replaced by vegetable oil containing phytosterol or phytosterol.
The invention also aims to provide the application of the composition for inhibiting the prostatic hyperplasia in the preparation of products for inhibiting the prostatic hyperplasia. The composition for inhibiting the prostatic hyperplasia has stable performance, can be processed into various dosage forms, and is suitable for processing and preparing products in various forms.
More preferably, the prostate hyperplasia-inhibiting product comprises a food, a health product or a pharmaceutical product.
Preferably, the product for inhibiting the prostatic hyperplasia further comprises auxiliary materials, wherein the auxiliary materials comprise a flavoring agent, a thickening agent, a disintegrating agent and a filling agent. On the premise of not influencing the main components of the composition for inhibiting the prostatic hyperplasia, the necessary auxiliary materials are added in the product to further enhance and provide the taste, the storage stability, the effect and the like of the product, and the person skilled in the art can select the common content according to the conventional standard.
Preferably, the dosage form of the prostate hyperplasia inhibition product comprises solid beverage, granules, capsules or tablets. The preparation form of the product can be adjusted according to the actual requirement on the premise of not influencing the component structure and the component stability of the composition.
The composition for inhibiting the prostatic hyperplasia has the beneficial effects that the turmeric, the lycopene, the mixed tocopherol and the phytosterol ester are compounded, and the curcumin in the turmeric can inhibit inflammatory factors and can inhibit the proliferation of prostate interstitial cells and induce the prostate interstitial cells to apoptosis; lycopene reduces DNA damage, improves oxidative stress defense; the mixed tocopherol can promote blood circulation and balance hormone level in vivo; the sterol in the plant sterol can compete with dihydrotestosterone, and can inhibit the combination of dihydrotestosterone and receptor, thereby improving prostatic hyperplasia. Through the synergistic interaction of the components, the traditional Chinese medicine composition can effectively inhibit the prostatic hyperplasia, and has better effect compared with the effect of singly using the turmeric and the lycopene. In addition, the composition for inhibiting the prostatic hyperplasia has high safety and no toxic or side effect. The invention also provides a preparation method of the composition for inhibiting the prostatic hyperplasia, and the preparation method has simple preparation process and can be used for industrial mass production. The invention also provides application of the composition for inhibiting the prostatic hyperplasia in preparation of a product for inhibiting the prostatic hyperplasia.
Detailed Description
Unless otherwise specified, the raw materials used in the examples of the present invention and comparative examples were commercially available, and the production equipment used was a commercially available common model. The turmeric in the examples and comparative examples of the present invention is an extract from the rhizome of turmeric, wherein the curcumin content is about 50%; the lycopene is a product produced by basf company; the mixed tocopherol is a product produced by Pasteur, and the content of the mixed tocopherol is about 90%; the phytosterol ester is a product produced by basf corporation, and the phytosterol ester content is about 97%.
For better illustrating the objects, technical solutions and advantages of the present invention, the present invention will be further described with reference to specific examples, which are intended to be understood in detail, but not intended to limit the present invention.
Example 1
One embodiment of the composition for inhibiting the prostatic hyperplasia comprises the following components in parts by weight: 12.5 parts of mixed tocopherol, 12.5 parts of lycopene, 12.5 parts of turmeric and 50 parts of phytosterol ester.
The preparation method of the composition for inhibiting prostatic hyperplasia comprises the following steps: sieving the mixed tocopherol, the lycopene, the turmeric and the phytosterol ester, weighing according to the weight parts, uniformly mixing and subpackaging to obtain the product for inhibiting the prostatic hyperplasia.
Example 2
One embodiment of the composition for inhibiting the prostatic hyperplasia comprises the following components in parts by weight: 25 parts of mixed tocopherol, 12.5 parts of lycopene, 12.5 parts of turmeric and 100 parts of phytosterol ester.
The preparation of the composition for inhibiting prostatic hyperplasia described in this example is the same as in example 1.
Example 3
One embodiment of the composition for inhibiting the prostatic hyperplasia comprises the following components in parts by weight: 50 parts of mixed tocopherol, 25 parts of lycopene, 12.5 parts of turmeric and 50 parts of phytosterol ester.
The preparation of the composition for inhibiting prostatic hyperplasia described in this example is the same as in example 1.
Example 4
One embodiment of the composition for inhibiting the prostatic hyperplasia comprises the following components in parts by weight: 12.5 parts of mixed tocopherol, 25 parts of lycopene, 25 parts of turmeric and 100 parts of phytosterol ester.
The preparation of the composition for inhibiting prostatic hyperplasia described in this example is the same as in example 1.
Example 5
One embodiment of the composition for inhibiting the prostatic hyperplasia comprises the following components in parts by weight: 25 parts of mixed tocopherol, 12.5 parts of lycopene, 25 parts of turmeric and 100 parts of phytosterol ester; the composition is used for preparing a preparation for inhibiting the hyperplasia of prostate, and the preparation further comprises: 30 parts of flavoring agent, 50 parts of microcrystalline cellulose, 40 parts of maltodextrin, 305 parts of povidone K, 2 parts of silicon dioxide and 3 parts of magnesium stearate.
The preparation method of the product for inhibiting the prostatic hyperplasia comprises the following steps: sieving the components, weighing the components in parts by weight, feeding the components into a mixer, uniformly mixing, granulating or not granulating, tabletting and bottling to obtain the product for inhibiting the prostatic hyperplasia. .
Example 6
One embodiment of the composition for inhibiting the prostatic hyperplasia comprises the following components in parts by weight: 12.5 parts of mixed tocopherol, 25 parts of lycopene, 12.5 parts of turmeric and 50 parts of phytosterol ester; the composition is used for preparing a preparation for inhibiting the hyperplasia of prostate, and the preparation further comprises: 4 parts of beeswax, 100 parts of gelatin, 50 parts of glycerol and 100 parts of purified water.
The preparation method of the product for inhibiting the prostatic hyperplasia comprises the following steps: weighing the components according to the corresponding weight parts, mixing, melting gelatin, pelleting, washing, drying, picking pills, packaging and preparing soft capsules to obtain the product for inhibiting the prostatic hyperplasia of the soft capsule dosage form.
Comparative example 1
The comparative example differs from example 1 only in that the composition of the comparative example has the following components: 100 parts of phytosterol ester.
Comparative example 2
The comparative example differs from example 1 only in that the composition of the comparative example has the following components: 50 parts of phytosterol ester.
Comparative example 3
The comparative example differs from example 1 only in that the composition of the comparative example has the following components: 12.5 parts mixed tocopherol, 12.5 parts lycopene and 12.5 parts turmeric.
Comparative example 4
The comparative example differs from example 1 only in that the composition of the comparative example has the following components: 25 parts of mixed tocopherol, 12.5 parts of lycopene and 12.5 parts of turmeric.
Comparative example 5
The comparative example differs from example 1 only in that the composition of the comparative example has the following components: 50 parts of mixed tocopherol, 25 parts of lycopene and 12.5 parts of turmeric.
Comparative example 6
The comparative example differs from example 1 only in that the composition of the comparative example has the following components: 15 parts of mixed tocopherol, 0.5 part of lycopene, 15 parts of turmeric and 100 parts of rape pollen.
In order to verify the influence of the composition for inhibiting the prostatic hyperplasia, prepared in the examples 1-4 and the comparative examples 1-6, on the prostatic hyperplasia cells, the composition products are used for the BPH-1 cell culture test.
The test uses human benign prostatic hyperplasia BPH-1 cells derived from prostatic epithelial tissue of a patient with prostatic hyperplasia;
the cell suspension and the added reagent used in the test are: 1640 culture solution, trypsin, PBS buffer solution, tetramethyl azozolium (MTT) and dimethyl sulfoxide (DMSO);
the experimental instruments needed to be used in the test are as follows: the device comprises a 96-pore plate, a biological safety cabinet, a carbon dioxide incubator, an enzyme-labeling instrument and an inverted microscope;
the test comprises the following specific steps: digesting human benign prostatic hyperplasia cell BPH-1, preparing single cell suspension with culture solution, and adjusting cell density to 1x104Inoculating each cell/well in 96-well plate with volume of 200 μ L, placing at 37 deg.C and 5% CO2After incubation for 24h in an incubator in a culture environment, the cells are adhered to the wall, and then the cells are treated for 48h by using test groups with different concentration ratios, wherein the dosages of the components of the test groups are shown in table 1. After treatment, the culture medium in the culture wells was removed, 20. mu.L of MTT solution (500mg MTT in 100ml PBS) was added to each well, incubation was continued for 4h, the culture was terminated, the culture supernatant in the wells was carefully aspirated, and the culture supernatant in the wells was aspirated after centrifugation was required for suspension cells. Add 150. mu.L DMSO solution per well, shake for 10min, fully melting the crystal. The absorbance of each well was measured on a microplate reader at 490nm, and the results are shown in table 2, where% cell proliferation ÷ component absorbance value ÷ blank control absorbance value × 100%.
TABLE 1
Figure BDA0002866447370000071
Figure BDA0002866447370000081
TABLE 2
Figure BDA0002866447370000082
Figure BDA0002866447370000091
Note: # is relative to the model control group, relative to the same concentration phytosterol ester group, ﹠ is relative to the same concentration mixed tocopherol + lycopene + turmeric; a, # # #, & & indicates p < 0.001; marked by, # #, & & indicates p < 0.01; significant, #, & indicates p < 0.05; the smaller the p-value, the more significant the difference.
As can be seen from table 2, the control group and the test group have very significant effects on the blank group, which indicates that the phytosterol ester, the mixed tocopherol, the lycopene and the turmeric group all have the effect of improving the prostatic hyperplasia, the BPH-1 hyperplasia rate% of the phytosterol ester under the concentration of 100 mug/mL and 50 mug/mL is 80% or more, the prostatic hyperplasia inhibition rate is less than or equal to 20%, and the effect on the prostatic hyperplasia inhibition rate is not particularly good.
But the combination of mixed tocopherol, lycopene, turmeric and phytosterol ester according to a certain proportion can obviously improve the hyperplasia of prostate. Under the condition of the same concentration, the test group and the control group have significance or extremely significance difference, so that the turmeric, the lycopene, the mixed tocopherol and the phytosterol ester have a synergistic effect after being compounded, and the test group has a better comparison ratio than the comparison ratio 6.
Finally, it should be noted that the above embodiments are only used for illustrating the technical solutions of the present invention and not for limiting the protection scope of the present invention, and although the present invention is described in detail with reference to the preferred embodiments, it should be understood by those skilled in the art that modifications or equivalent substitutions can be made on the technical solutions of the present invention without departing from the spirit and scope of the technical solutions of the present invention.

Claims (6)

1. A composition for inhibiting prostatic hyperplasia, comprising the following components: mixed tocopherols, lycopene and phytosterol esters, further comprising turmeric; the curcumin content in the turmeric is 40-60%.
2. The composition for inhibiting prostatic hyperplasia according to claim 1, which comprises the following components in parts by weight: 12.5-50 parts of mixed tocopherol, 12.5-25 parts of lycopene, 12.5-25 parts of turmeric and 50-100 parts of phytosterol ester.
3. The method of preparing a composition for inhibiting prostatic hyperplasia according to any one of claims 1 to 2, wherein the method comprises: mixing mixed tocopherol, lycopene, turmeric and phytosterol ester uniformly to obtain the composition for inhibiting the prostatic hyperplasia.
4. Use of the composition for inhibiting prostatic hyperplasia according to any one of claims 1-2 in the preparation of a product for inhibiting prostatic hyperplasia.
5. The use of the composition for inhibiting prostatic hyperplasia according to claim 4 in the preparation of a product for inhibiting prostatic hyperplasia, wherein the components of the product for inhibiting prostatic hyperplasia further comprise adjuvants, and the adjuvants comprise a flavoring agent, a thickening agent, a disintegrating agent and a filler.
6. The use of the composition for inhibiting prostatic hyperplasia according to claim 5 in the preparation of a product for inhibiting prostatic hyperplasia, wherein the dosage form of the product for inhibiting prostatic hyperplasia comprises solid beverage, granules, capsules or tablets.
CN202011598714.9A 2020-12-28 2020-12-28 Composition for inhibiting prostatic hyperplasia Pending CN112603982A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202011598714.9A CN112603982A (en) 2020-12-28 2020-12-28 Composition for inhibiting prostatic hyperplasia

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202011598714.9A CN112603982A (en) 2020-12-28 2020-12-28 Composition for inhibiting prostatic hyperplasia

Publications (1)

Publication Number Publication Date
CN112603982A true CN112603982A (en) 2021-04-06

Family

ID=75249125

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202011598714.9A Pending CN112603982A (en) 2020-12-28 2020-12-28 Composition for inhibiting prostatic hyperplasia

Country Status (1)

Country Link
CN (1) CN112603982A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113456609A (en) * 2021-07-29 2021-10-01 江苏艾兰得营养品有限公司 Compound preparation beneficial to maintaining prostate health and preparation method thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103619329A (en) * 2011-04-07 2014-03-05 利库德有限公司 Synergistic compositions and methods
CN105748529A (en) * 2016-04-25 2016-07-13 汤臣倍健股份有限公司 Combination with effect of inhibiting benign prostatic hyperplasia and application thereof
CN108451979A (en) * 2018-06-28 2018-08-28 新疆金骏阳光生物科技有限公司 A kind of lycopene compound preparation and its application with auxiliary treatment prostate cancer

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103619329A (en) * 2011-04-07 2014-03-05 利库德有限公司 Synergistic compositions and methods
CN105748529A (en) * 2016-04-25 2016-07-13 汤臣倍健股份有限公司 Combination with effect of inhibiting benign prostatic hyperplasia and application thereof
CN108451979A (en) * 2018-06-28 2018-08-28 新疆金骏阳光生物科技有限公司 A kind of lycopene compound preparation and its application with auxiliary treatment prostate cancer

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113456609A (en) * 2021-07-29 2021-10-01 江苏艾兰得营养品有限公司 Compound preparation beneficial to maintaining prostate health and preparation method thereof

Similar Documents

Publication Publication Date Title
CN113150867B (en) Preparation method of ganoderma lucidum extract oil rich in ganoderma lucidum triterpenes
CN104982928B (en) A kind of japanese yew fruit health care ferment and preparation method thereof
RU2657757C2 (en) Novel extracts of cynara scolymus, coffea spp. and olea europaea for the treatment of metabolic syndrome
US10624942B2 (en) Composition for amelioration of peri- and post-menopausal symptoms and a process for producing the same
CN106962933B (en) Application of nymphaea hybrid extract and composition thereof in preventing obesity and improving intestinal flora
CN101836725A (en) Application of red rice residue product in preparing health-care food for lowering blood fat
KR20120003693A (en) Anti-obesity composition comprising red grape extracts, green tea extracts, soybean extracts, and l-carnitine
CN109602756A (en) A kind of sobering-up composition and the preparation method and application thereof
KR20090019760A (en) Pharmaceutical composition containing chenopodium ambrosioides extract and its preparing process and application
CN112603982A (en) Composition for inhibiting prostatic hyperplasia
CN110882359A (en) Naqu preparation and preparation method thereof
CN109453267A (en) Sobering-up composition and the preparation method and application thereof
Ye et al. Water extract of Ferula lehmanni Boiss. prevents high-fat diet-induced overweight and liver injury by modulating the intestinal microbiota in mice
CN105796764B (en) Preparation method and application of negundo chastetree fruit total lignans
CN112715938A (en) Composition for inhibiting prostatic hyperplasia
CN114259526A (en) Formula of blood lipid-lowering medicine or blood lipid-lowering health-care product and preparation method thereof
CN112656915A (en) Composition for inhibiting prostatic hyperplasia
WO2007137602A1 (en) Method of producing a liquid oral or otherwise applicable composition for administration to human beings and animals, liquid oral or otherwise applicable composition and its use of the composition for the manufacture of a product for functional nutrition
CN102228666A (en) Composition prepared from pine pollen and curcuma, preparation method thereof, and application of composition in preparing medicament for treating inflammatory bowel disease
CN105232802B (en) Procyanidine composition with blood fat reducing effect and preparation method and application thereof
CN113144134A (en) Pharmaceutical composition for inhibiting prostate cancer and application thereof
CN113577220A (en) Medicinal composition for inhibiting prostate cancer and application thereof
CN112569337A (en) Composition for inhibiting prostatic hyperplasia
CN115645464B (en) Traditional Chinese medicine composition for treating atherosclerosis and fatty liver and application thereof
CN112807403A (en) Application of composition in preparation of product for inhibiting prostate cancer

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20210406